Literature DB >> 28351184

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Xueyan Chen1, Megan Othus2, Brent L Wood1, Roland B Walter3,4,5, Mary-Elizabeth M Percival3,4, Pamela S Becker3,4,5, Paul C Hendrie4, Frederick R Appelbaum3,5, Elihu H Estey3,4,5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28351184     DOI： 10.1080/10428194.2017.1307359

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.

Authors:  Thomas Köhnke; Veit Bücklein; Sandra Rechkemmer; Stephanie Schneider; Maja Rothenberg-Thurley; Klaus H Metzeler; Maria-Cristina Sauerland; Wolfgang Hiddemann; Karsten Spiekermann; Marion Subklewe
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 2.  The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Authors:  Francesco Buccisano; Christopher S Hourigan; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.